Mutation analysis of the CDKN2A promoter in Australian melanoma families

P M Pollock1, M S Stark, J M Palmer

  • 1Joint Experimental Oncology Program of the Queensland Institute of Medical Research, University of Queensland, and the Queensland Cancer Fund, P.O. Royal Brisbane Hospital, Brisbane, Australia.

Insights

Investigating noncoding CDKN2A mutations in Australian melanoma families revealed no evidence of disease-associated mutations in the promoter or 5' UTR. These findings suggest these regions play a minimal role in melanoma predisposition.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Melanoma predisposition is linked to 9p21-22, with germline CDKN2A mutations identified in about half of affected families.
  • A previously reported mutation in the 5' UTR of CDKN2A (-34 position) creates a novel start codon, reducing translation from the wild-type AUG.
  • This Canadian mutation is hypothesized to be of British origin, prompting investigation into noncoding CDKN2A regions in other populations.

Purpose of the Study:

  • To investigate the role of noncoding CDKN2A mutations in Australian melanoma families.
  • To sequence the 5' UTR and promoter regions of CDKN2A in Australian melanoma families.
  • To assess the impact of potential noncoding mutations on CDKN2A expression and melanoma predisposition.

Main Methods:

  • Sequencing of 1,327 base pairs of CDKN2A (including 5' UTR, promoter, exon 1, and intron 1) in 110 Australian melanoma families.
  • Sequencing of 431 bp upstream of the start codon in 253 additional affected probands.
  • Allele-specific expression analysis using reverse transcription polymerase chain reaction and automated sequencing in 31 families.

Main Results:

  • Known polymorphisms and four novel variants in the CDKN2A 5' UTR and promoter were detected.
  • The previously reported -34 mutation and other disease-associated mutations were not found in any family members.
  • Allele-specific expression analysis confirmed expression from both CDKN2A alleles in all tested family members, with no evidence of transcriptional silencing.

Conclusions:

  • The study found no evidence of disease-associated mutations in the promoter or 5' UTR of CDKN2A in the investigated Australian melanoma families.
  • The lack of identified mutations and normal allele expression suggests that these noncoding regions play a very limited role in melanoma predisposition in this cohort.
  • Further research may be needed to explore other genetic or environmental factors contributing to melanoma risk in families with 9p21-22 linkage but no identified CDKN2A coding or noncoding mutations.